Across TCGA pan-cancer cohorts, SRGAP3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SRGAP3 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SRGAP3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SRGAP3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where SRGAP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.895	0.266	.006	18	view →
GBM	DFS	Tertile	All	0.848	0.602	.002	15	view →
CCRCC	OS	Tertile	All	0.607	1.000	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SRGAP3 tumor-vs-normal RNA expression · all SRGAP3 data types